ClinicalTrials.gg
RecruitingNCT07208136Updated Dec 1, 2025

A Study of JMKX005425 in Patients With MSI-H/dMMR Advanced Solid Tumors

A Phase 1 interventional study of JMKX005425 in Advanced Solid Tumors, sponsored by Jemincare. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-12-01.

Sponsored by Jemincare · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
102
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This is a first-in-human, Phase I, open-label, multi-center, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of JMKX005425 in subjects with microsatellite instability-high (MSI) and/or mismatch repair deficiency (dMMR) advanced solid tumors.

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

Jemincare is the lead sponsor of 37 studies on the registry; 30 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have a microsatellite instability-high (MSI) and/or mismatch repair deficiency (dMMR), or cytologically documented advanced solid tumor.
  2. Has at least one per v1.1.
  3. Has a of ≥ 12 weeks.
  4. Adequate organ function.

Exclusion criteria

Exclusion Criteria:

  1. Toxicities from prior anti-tumor therapy has not recovered to Grade 1 or below per v5.0.
  2. History of prior in the past 3 years, with the exception of curatively treated malignancies.
  3. Has the dysphagia, or impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of study drug.
  4. Has the severe chronic or active infection
  5. Has a history of severe cardiovascular disease.
  6. Subject is pregnant or breastfeeding.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
102 participants (estimated)

Study arms

  • Experimental
    JMKX005425

    Subjects will take a pre-specified dose of JMKX005425.

    Drug: JMKX005425

Interventions

  • DrugJMKX005425

    JMKX005425 administered orally.

06

What researchers measure

Primary outcomes

  1. Number of participants with dose limiting toxicities (DLTs), AEs, serious AEs (SAEs)

    To assess the safety and tolerability of JMKX005425.

    Time frame: up to 2 years

Secondary outcomes

  1. maximum plasma concentration (Cmax)

    Maximum observed concentration.

    Time frame: Up to 2 months

  2. maximum plasma concentration (Tmax)

    Time to reach maximum observed plasma concentration.

    Time frame: Up to 2 months

  3. Objective Response Rate (ORR)

    ORR defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

    Time frame: Up to 2 years

  4. Disease Control Rate (DCR)

    DCR is the percentage of patients with a best overall response of CR or PR or Stable Disease (SD) per RECIST v1.1.

    Time frame: Up to 2 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Dec 2027, 26 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2025
First posted
Oct 6, 2025
StartActual
Oct 22, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2028
Last update
Dec 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07208136
Lead sponsor
Jemincare
Responsible party
Sponsor
First posted
Oct 6, 2025
Start date
Oct 22, 2025
Primary completion
Dec 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Dec 1, 2025

Study contacts

Lu Chen
Contact
chenlu5@jeyoupharma.com
+86 17717684840
Lin Shen
principal investigator · Peking University Cancer Hospital & Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion